Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
BOLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.76 - $14.37
Previous CloseN/A
Volume72.19K
Average Volume (3M)19.36K
Market Cap
$9.73M
Enterprise Value-$305.28K
Total Cash (Recent Filing)$34.77M
Total Debt (Recent Filing)$24.18M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 06, 2025EPS Estimate
-5.97Last Dividend Ex-Date
Aug 29, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding1,919,441
10 Day Avg. Volume15,025
30 Day Avg. Volume19,363
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$75.00Price Target Upside1469.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical ProgressBolt Biotherapeutics has made encouraging progress on their two lead assets, BDC-3042 and BDC-4182.
Market CompetitivenessBDC-4182 outperformed other cytotoxic claudin 18.2 ADCs in preclinical models, suggesting potential competitiveness in the market.
Safety ProfileBDC-4182 was tolerated in non-human primates at the highest dose tested with an acceptable safety profile.
Bears Say
Clinical UncertaintyEnrolled patients will have a wide range of CLDN18.2 expression levels, which might lead to a mixed result.
Competitive LandscapeSeveral peer companies have ongoing or discontinued programs targeting CLDN18.2, indicating a competitive landscape for Bolt Biotherapeutics.
Financial UncertaintyThere is uncertainty whether Bolt secures attractive enough economic terms to meaningfully extend their cash runway beyond mid-2026.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $4.76 and its highest was $14.37 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $9.73M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 77 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Aug 14, 2025. The company reported -$4.46 earnings per share for the quarter, beating the consensus estimate of -$6.3 by $1.84.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -5.97.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,919,441 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$4.46 in its last earnings report, beating expectations of -$6.3. Following the earnings report the stock price went down -5.331%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
Bolt Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.00 (1469.04% Upside)
$75.00 (1469.04% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.39%
12-Months-Change
Fundamentals
Return on Equity
-81.33%
Trailing 12-Months
Asset Growth
-39.20%
Trailing 12-Months
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
BOLT Stock 12 Month Forecast
Average Price Target
$75.00
▲(1469.04% Upside)
Technical Analysis
Ownership Overview
3.08% Insiders
79.06% Mutual Funds
<0.01% Other Institutional Investors
14.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---